Mitch A Phelps

List of Publications by Year
in descending order

159 papers	5,634 citations	94433 37 h-index	91884 69 g-index
161 all docs	161 docs citations	161 times ranked	8953 citing authors

#	Article	IF	Citations
1	Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood, 2007, 109, 399-404.	1.4	367
2	Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells. Journal of Extracellular Vesicles, 2017, 6, 1324730.	12.2	357
3	Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers. Journal of Clinical Oncology, 2011, 29, 2357-2363.	1.6	272
4	Discovery and Mechanism of Highly Efficient Cyclic Cell-Penetrating Peptides. Biochemistry, 2016, 55, 2601-2612.	2.5	232
5	Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease. Journal of Clinical Oncology, 2009, 27, 6012-6018.	1.6	212
6	miR-221 Silencing Blocks Hepatocellular Carcinoma and Promotes Survival. Cancer Research, 2011, 71, 7608-7616.	0.9	206
7	Favorable Effects of Weak Acids on Negative-Ion Electrospray Ionization Mass Spectrometry. Analytical Chemistry, 2004, 76, 839-847.	6.5	182
8	Selective Androgen Receptor Modulator Treatment Improves Muscle Strength and Body Composition and Prevents Bone Loss in Orchidectomized Rats. Endocrinology, 2005, 146, 4887-4897.	2.8	173
9	Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood, 2009, 113, 2637-2645.	1.4	152
10	The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research. Cell, 2019, 177, 231-242.	28.9	152
11	Pharmacogenomic testing: Relevance in medical practice. Cleveland Clinic Journal of Medicine, 2011, 78, 243-257.	1.3	126
12	REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer. Clinical Cancer Research, 2010, 16, 5564-5572.	7.0	120
13	Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study. PLoS Medicine, 2017, 14, e1002382.	8.4	107
14	Achieving the Promise of Therapeutic Extracellular Vesicles: The Devil is in Details of Therapeutic Loading. Pharmaceutical Research, 2017, 34, 1053-1066.	3.5	94
15	Discovery of Anticancer Agents of Diverse Natural Origin. Anticancer Research, 2016, 36, 5623-5638.	1.1	94
16	Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias. Journal of Clinical Oncology, 2010, 28, 4919-4925.	1.6	82
17	Structurally Modified Curcumin Analogs Inhibit STAT3 Phosphorylation and Promote Apoptosis of Human Renal Cell Carcinoma and Melanoma Cell Lines. PLoS ONE, 2012, 7, e40724.	2.5	80
18	Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomideâ€“CCI-779 Interaction via P-Glycoprotein. Journal of Clinical Oncology, 2011, 29, 3427-3434.	1.6	77

#	Article	IF	Citations
19	Modeling of active transport systems. Advanced Drug Delivery Reviews, 2002, 54, 329-354.	13.7	76
20	PRMT5 as a druggable target for glioblastoma therapy. Neuro-Oncology, 2018, 20, 753-763.	1.2	75
21	Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers. Journal of Proteomics, 2016, 136, 89-98.	2.4	68
22	Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration. Scientific Reports, 2017, 7, 15424.	3.3	68
23	Low active loading of cargo into engineered extracellular vesicles results in inefficient miRNA mimic delivery. Journal of Extracellular Vesicles, 2017, 6, 1333882.	12.2	65
24	Resistance to the Translation Initiation Inhibitor Silvestrol is Mediated by ABCB1/P-Glycoprotein Overexpression in Acute Lymphoblastic Leukemia Cells. AAPS Journal, 2011, 13, 357-64.	4.4	63
25	Topology Scanning and Putative Three-Dimensional Structure of the Extracellular Binding Domains of the Apical Sodium-Dependent Bile Acid Transporter (SLC10A2)â€. Biochemistry, 2004, 43, 11380-11392.	2.5	62
26	Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer. Scientific Reports, 2015, 5, 12122.	3.3	58
27	Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias. Haematologica, 2010, 95, 1098-1105.	3.5	50
28	Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples. Modern Pathology, 2012, 25, 1333-1344.	5.5	48
29	Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia. Blood, 2015, 125, 2689-2692.	1.4	47
30	Flavopiridol Pharmacogenetics: Clinical and Functional Evidence for the Role of SLCO1B1/OATP1B1 in Flavopiridol Disposition. PLoS ONE, 2010, 5, e13792.	2.5	45
31	A novel liposomal formulation of flavopiridol. International Journal of Pharmaceutics, 2009, 365, 170-174.	5.2	43
32	A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. Leukemia and Lymphoma, 2017, 58, 2310-2318.	1.3	43
33	Registered report: Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. ELife, 2016, 5, .	6.0	43
34	Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. Leukemia, 2011, 25, 1444-1451.	7.2	42
35	Characterization of Silvestrol Pharmacokinetics in Mice Using Liquid Chromatographyâ€“Tandem Mass Spectrometry. AAPS Journal, 2011, 13, 347-56.	4.4	41
36	Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma, 2013, 54, 1996-2002.	1.3	41

#	Article	IF	Citations
37	SUV39H1 Represses the Expression of Cytotoxic T-Lymphocyte Effector Genes to Promote Colon Tumor Immune Evasion. Cancer Immunology Research, 2019, 7, 414-427.	3.4	40
38	Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. Blood, 2021, 137, 3473-3483.	1.4	40
39	DNA Origami Nanostructures Elicit Doseâ€Dependent Immunogenicity and Are Nontoxic up to High Doses In Vivo. Small, 2022, 18, .	10.0	40
40	Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia. Leukemia, 2015, 29, 346-355.	7.2	36
41	Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies. Clinical Cancer Research, 2013, 19, 347-356.	7.0	34
42	A novel liposomal formulation of FTY720 (Fingolimod) for promising enhanced targeted delivery. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 393-400.	3.3	34
43	A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leukemia and Lymphoma, 2009, 50, 1958-1963.	1.3	32
44	ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model. Blood, 2019, 134, 432-444.	1.4	32
45	Involvement of Endocytic Organelles in the Subcellular Trafficking and Localization of Riboflavin. Journal of Pharmacology and Experimental Therapeutics, 2003, 306, 681-687.	2.5	31
46	The combination of milatuzumab, a humanized antiâ€CD74 antibody, and veltuzumab, a humanized antiâ€CD20 antibody, demonstrates activity in patients with relapsed and refractory Bâ€cell nonâ€Hodgkin lymphoma. British Journal of Haematology, 2015, 169, 701-710.	2.5	31
47	A phase I trial of flavopiridol in relapsed multiple myeloma. Cancer Chemotherapy and Pharmacology, 2014, 73, 249-257.	2.3	30
48	Intracellular Processing of Riboflavin in Human Breast Cancer Cells. Molecular Pharmaceutics, 2008, 5, 839-848.	4.6	29
49	Pharmacokinetics and Tissue Disposition of Lenalidomide in Mice. AAPS Journal, 2012, 14, 872-882.	4.4	29
50	Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant. Molecular Carcinogenesis, 2017, 56, 1722-1732.	2.7	28
51	Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML. Investigational New Drugs, 2020, 38, 340-349.	2.6	28
52	Development and Validation of a Highly Sensitive Liquid Chromatography/Mass Spectrometry Method for Simultaneous Quantification of Lenalidomide and Flavopiridol in Human Plasma. Therapeutic Drug Monitoring, 2008, 30, 620-627.	2.0	27
53	A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors. Investigational New Drugs, 2013, 31, 685-695.	2.6	26
54	Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia. Leukemia Research, 2013, 37, 1195-1199.	0.8	26

#	Article	IF	Citations
55	Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory nonâ€Hodgkin's lymphoma. American Journal of Hematology, 2014, 89, 19-24.	4.1	26
56	CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128. Oncotarget, 2018, 9, 26032-26045.	1.8	26
57	Comparative cellular pharmacokinetics and pharmacodynamics of siRNA delivery by SPANosomes and by cationic liposomes. Nanomedicine: Nanotechnology, Biology, and Medicine, 2013, 9, 504-513.	3.3	25
58	Race and Ethnicity in Cancer Therapy: What Have We Learned?. Clinical Pharmacology and Therapeutics, 2014, 95, 403-412.	4.7	25
59	A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer. Investigational New Drugs, 2020, 38, 1400-1410.	2.6	25
60	A Novel Rhodamineâ^'Riboflavin Conjugate Probe Exhibits Distinct Fluorescence Resonance Energy Transfer that Enables Riboflavin Trafficking and Subcellular Localization Studies. Molecular Pharmaceutics, 2004, 1, 257-266.	4.6	24
61	6Î²-Naltrexol, a Peripherally Selective Opioid Antagonist that Inhibits Morphine-Induced Slowing of Gastrointestinal Transit: An Exploratory Study. Pain Medicine, 2011, 12, 1727-1737.	1.9	24
62	A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors. Investigational New Drugs, 2012, 30, 629-638.	2.6	24
63	Liquid chromatographyâ€“tandem mass spectrometry assay for the simultaneous quantification of simvastatin, lovastatin, atorvastatin, and their major metabolites in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 983-984, 18-25.	2.3	24
64	Phyllanthusmin Derivatives Induce Apoptosis and Reduce Tumor Burden in High-Grade Serous Ovarian Cancer by Late-Stage Autophagy Inhibition. Molecular Cancer Therapeutics, 2018, 17, 2123-2135.	4.1	24
65	Cachectic Cancer Patients: Immune to Checkpoint Inhibitor Therapy?. Clinical Cancer Research, 2018, 24, 5787-5789.	7.0	24
66	A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 347-353.	0.4	23
67	Cytoskeletal motors and cargo in membrane trafficking: opportunities for high specificity in drug intervention. Drug Discovery Today, 2003, 8, 494-502.	6.4	22
68	Inhibitors of Tubulin Assembly Identified through Screening a Compound Library. Chemical Biology and Drug Design, 2008, 72, 513-524.	3.2	22
69	Recognition, Cointernalization, and Recycling of an Avian Riboflavin Carrier Protein in Human Placental Trophoblasts. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 465-472.	2.5	21
70	Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue. Journal of Pharmaceutical and Biomedical Analysis, 2014, 88, 262-268.	2.8	21
71	Erlotinib in African Americans With Advanced Nonâ€“Small Cell Lung Cancer: A Prospective Randomized Study With Genetic and Pharmacokinetic Analyses. Clinical Pharmacology and Therapeutics, 2014, 96, 182-191.	4.7	21
72	Antikinetoplastid antimitotic activity and metabolic stability of dinitroaniline sulfonamides and benzamides. Bioorganic and Medicinal Chemistry, 2006, 14, 5699-5710.	3.0	20

#	Article	IF	Citations
73	The Role of Malnutrition and Muscle Wasting in Advanced Lung Cancer. Current Oncology Reports, 2020, 22, 54.	4.0	20
74	A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol. Clinical Cancer Research, 2013, 19, 1269-1280.	7.0	19
75	OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. Blood, 2015, 125, 284-295.	1.4	19
76	Discovery of Anticancer Agents of Diverse Natural Origin. Journal of Natural Products, 2022, 85, 702-719.	3.0	19
77	Approaches to handling missing or â€œproblematicâ€•pharmacology data: Pharmacokinetics. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 291-308.	2.5	18
78	Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. Haematologica, 2012, 97, 423-427.	3.5	17
79	Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 868, 110-115.	2.3	16
80	Site Specific Discrete PEGylation of ¹²⁴I-Labeled mCC49 Fabâ€² Fragments Improves Tumor MicroPET/CT Imaging in Mice. Bioconjugate Chemistry, 2013, 24, 1945-1954.	3.6	16
81	ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma inÂvitro and inÂvivo. Experimental Hematology, 2015, 43, 770-774.e2.	0.4	16
82	Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. PLoS ONE, 2017, 12, e0181885.	2.5	16
83	A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. Cancer Chemotherapy and Pharmacology, 2021, 87, 599-611.	2.3	16
84	<scp>R</scp>educed occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL). American Journal of Hematology, 2015, 90, 327-333.	4.1	15
85	Irinotecan Pharmacogenetics: A Finished Puzzle?. Journal of Clinical Oncology, 2014, 32, 2287-2289.	1.6	14
86	PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia. Blood, 2022, 139, 1340-1358.	1.4	14
87	Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma. Leukemia and Lymphoma, 2015, 56, 2834-2840.	1.3	13
88	In vitroimmunotoxicity assessment of culture-derived extracellular vesicles in human monocytes. Journal of Immunotoxicology, 2016, 13, 652-665.	1.7	13
89	A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia and Lymphoma, 2016, 57, 2212-2215.	1.3	13
90	Phase I study of AR-42 and decitabine in acute myeloid leukemia. Leukemia and Lymphoma, 2020, 61, 1484-1492.	1.3	13

#	Article	IF	Citations
91	Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy. Clinical Lung Cancer, 2022, 23, 345-355.	2.6	13
92	Pharmacokinetics of methylprednisolone acetate after intra-articular administration and subsequent suppression of endogenous hydrocortisone secretion in exercising horses. American Journal of Veterinary Research, 2012, 73, 1453-1461.	0.6	12
93	Development and validation of sensitive liquid chromatography/tandem mass spectrometry method for quantification of bendamustine in mouse brain tissue. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 905, 141-144.	2.3	12
94	A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia. Leukemia Research, 2014, 38, 1025-1029.	0.8	11
95	Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents. AAPS Journal, 2016, 18, 737-745.	4.4	11
96	Pharmacokineticâ€Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving Highâ€Dose Melphalan for Autologous Stem Cell Transplant. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 748-758.	2.5	11
97	Toxicology and Biodistribution Studies for MGH2.1, an Oncolytic Virus that Expresses Two Prodrug-activating Genes, in Combination with Prodrugs. Molecular Therapy - Nucleic Acids, 2013, 2, e113.	5.1	10
98	Pharmacokinetics of intra-articular betamethasone sodium phosphate and betamethasone acetate and endogenous hydrocortisone suppression in exercising horses. Journal of Veterinary Pharmacology and Therapeutics, 2016, 39, 22-26.	1.3	10
99	Preferential Delivery of an Opioid Antagonist to the Fetal Brain in Pregnant Mice. Journal of Pharmacology and Experimental Therapeutics, 2016, 358, 22-30.	2.5	10
100	A Single Nucleotide Polymorphism in SLC7A5 Was Associated With Clinical Response in Multiple Myeloma Patients. Anticancer Research, 2019, 39, 67-72.	1.1	10
101	Inhibition of androgen/AR signaling inhibits diethylnitrosamine (DEN) induced tumour initiation and remodels liver immune cell networks. Scientific Reports, 2021, 11, 3646.	3.3	10
102	Pharmacokinetics of oral ivabradine in healthy cats. Journal of Veterinary Pharmacology and Therapeutics, 2011, 34, 469-475.	1.3	9
103	Influence of exercise on the distribution of technetium Tc 99m medronate following intra-articular injection in horses. American Journal of Veterinary Research, 2012, 73, 418-425.	0.6	8
104	Development of a physiologically based pharmacokinetic model for intravenous lenalidomide in mice. Cancer Chemotherapy and Pharmacology, 2019, 84, 1073-1087.	2.3	8
105	Population pharmacokinetics of lenalidomide in patients with Bâ€cell malignancies. British Journal of Clinical Pharmacology, 2019, 85, 924-934.	2.4	8
106	Development and validation of a rapid and sensitive high-performance liquid chromatographyâ€“mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 871, 15-21.	2.3	7
107	Optimising time samples for determining area under the curve of pharmacokinetic data using non-compartmental analysis. Journal of Pharmacy and Pharmacology, 2019, 71, 1635-1644.	2.4	7
108	XRCC1â€mediated DNA repair is associated with progressionâ€free survival of multiple myeloma patients after autologous stem cell transplant. Molecular Carcinogenesis, 2019, 58, 2327-2339.	2.7	7

#	Article	IF	Citations
109	Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer. Gynecologic Oncology, 2021, 162, 619-625.	1.4	7
110	Letter to the Editor: Exposureâ€“response or clearanceâ€“response relationship in immune checkpoint therapy?â€”A comment on â€˜correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancerâ€™ by Basak etÂal. European Journal of Cancer, 2019, 114, 25-26.	2.8	6
111	Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans. JCSM Rapid Communications, 2021, 4, 232-244.	1.6	6
112	Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer. Expert Review of Anticancer Therapy, 2022, 22, 861-874.	2.4	6
113	Institutional Profile: Program in Pharmacogenomics at the Ohio State University Medical Center. Pharmacogenomics, 2012, 13, 751-756.	1.3	5
114	NK Cellâ€“Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines. Cancer Immunology Research, 2016, 4, 323-336.	3.4	5
115	Replication Study: Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. ELife, 2020, 9, .	6.0	5
116	Flavopiridol in Chronic Lymphocytic Leukemia. Clinical Leukemia, 2007, 1, 292-297.	0.2	4
117	Standard Pentostatin Dose Reductions in Renal Insufficiency Are Not Adequate: Selected Patients with Steroid-Refractory Acute Graft-Versus-Host Disease. Clinical Pharmacokinetics, 2013, 52, 705-712.	3.5	4
118	Quantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatographyâ€“tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2014, 98, 160-165.	2.8	4
119	G-CSF improves safety when you start the day after autologous transplant in multiple myeloma. Leukemia and Lymphoma, 2017, 58, 2947-2951.	1.3	4
120	Association of ANRIL Polymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation. Anticancer Research, 2020, 40, 5707-5713.	1.1	4
121	Flavopiridol Can Be Safely Dose Escalated in Relapsed CLL Patients: Achievement of Target Cmax Results in Improved Clinical Activity.. Blood, 2006, 108, 2845-2845.	1.4	4
122	A phase 1 study of AR-42 in patients with advanced solid tumors, including nervous system tumors.. Journal of Clinical Oncology, 2016, 34, 2558-2558.	1.6	4
123	Preparation and Evaluation of a Novel Class of Amphiphilic Amines as Antitumor Agents and Nanocarriers for Bioactive Molecules. Pharmaceutical Research, 2016, 33, 2722-2735.	3.5	3
124	Plasma pharmacokinetics and bioavailability of verticillin A following different routes of administration in mice using liquid chromatography tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2017, 139, 187-192.	2.8	3
125	Pharmacokinetics and Tolerability of the Novel Non-immunosuppressive Fingolimod Derivative, OSU-2S, in Dogs and Comparisons with Data in Mice and Rats. AAPS Journal, 2020, 22, 92.	4.4	3
126	Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2020, 26, 6187-6195.	7.0	3

#	Article	IF	Citations
127	Pharmacological Prevention of Neonatal Opioid Withdrawal in a Pregnant Guinea Pig Model. Frontiers in Pharmacology, 2020, 11, 613328.	3.5	3
128	Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).. Blood, 2007, 110, 3104-3104.	1.4	3
129	2-Hour Cryotherapy Effectively Reduces Severe Mucositis Associated with High-Dose Melphalan Followed By Stem Cell Rescue: Results from a Randomized Trial. Blood, 2014, 124, 3960-3960.	1.4	3
130	Acetaminophen Pediatric Dose Selection. Clinical Pediatrics, 2012, 51, 1030-1031.	0.8	2
131	Analysis of the transport of and cytotoxic effects for nalbuphine solution in corneal cells. American Journal of Veterinary Research, 2012, 73, 1987-1995.	0.6	2
132	Establishing a clinical pharmacology fellowship program for physicians, pharmacists, and pharmacologists: a newly accredited interdisciplinary training program at the Ohio State University. Advances in Medical Education and Practice, 2014, 5, 191.	1.5	2
133	Phase I Trial of Dabrafenib and Pazopanib in BRAF Mutated Advanced Malignancies. JCO Precision Oncology, 2018, 2, 1-19.	3.0	2
134	A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and highâ€risk myelodysplastic syndrome. American Journal of Hematology, 2020, 95, 1457-1465.	4.1	2
135	Phase 1 Evaluation of Oral Tetrahydrouridine-Decitabine As Non-Cytotoxic Epigenetic Disease Modification for Sickle Cell Disease. Blood, 2016, 128, 124-124.	1.4	2
136	ROR1 targeted immunoliposomal delivery of OSU-2S shows selective cytotoxicity in t(1;19)(q23;p13) translocated B-cell acute lymphoblastic leukemia. Leukemia Research, 2022, 118, 106872.	0.8	2
137	The Neonatal Fc Receptor Is Elevated in Monocyte-Derived Immune Cells in Pancreatic Cancer. International Journal of Molecular Sciences, 2022, 23, 7066.	4.1	2
138	Reply to N. Chen et al. Journal of Clinical Oncology, 2012, 30, 341-342.	1.6	1
139	A Prospective, Double-Blinded, Observational Clinical Cohort Study of the Association Between Tacrolimus Exposure and CYP3A4, CYP3A5 Genotypes in Adult Hematopoietic Stem Cell Transplant Recipients. Biology of Blood and Marrow Transplantation, 2013, 19, S380.	2.0	1
140	Rituximab immunotherapy: itâ€™s getting personal. Blood, 2017, 129, 2595-2596.	1.4	1
141	Tumor Antigen ROR1 Targeted Delivery Of FTY720 Derivative OSU-2S Prolongs Survival In ROR1 Engineered Mouse Model Of Chronic Lymphocytic Leukemia. Blood, 2013, 122, 4168-4168.	1.4	1
142	Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46, 807-816.	1.6	1
143	Phase I Trial of Flavopiridol In Relapsed Myeloma: Brief Response In t(4;14) with Significant Neutropenia. Blood, 2010, 116, 1933-1933.	1.4	1
144	Abstract 2068: Engineering of hairpin loop enhances the loading of endogenously expressed pre-miRNA into extracellular vesicles. , 2016, , .		1

#	Article	IF	Citations
145	Updated Results of a Phase I Study of Flavopiridol in Acute Leukemias Using a Novel, Pharmacokinetically Derived Schedule: Clinical Activity Including Hyperacute Tumor Lysis Syndrome (TLS), Pharmacokinetics (PK), and Pharmacodynamics (PD).. Blood, 2006, 108, 4578-4578.	1.4	0
146	Abstract 4711: Silencing of miR-221 with anti-microRNA oligonucleotides is an effective therapeutic for hepatocellular carcinoma. , 2011, , .		0
147	Abstract 5473: The contribution of P-glycoprotein to clinical pharmacokinetic interactions between lenalidomide and temsirolimus. , 2011, , .		0
148	Abstract 124: Cellular context in epigenetics: Per-cell quantitation of miR-let-7d and its putative target in caspase-3 in reovirus-infected cancer cells. , 2011, , .		0
149	Abstract 1721: Resistance to silvestrol is mediated by MDR1/Pgp over-expression in a lymphoblastic leukemia cell line and is reversible by treatment with rapamycin. , 2011, , .		0
150	Priming of Mir-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine.. Blood, 2012, 120, 2619-2619.	1.4	0
151	Abstract 4481: Myeloperoxidase as a determinant for activity of etoposide (VP-16) and other phenolic and non-phenolic anticancer agents: implications for drug-induced leukemogenesis.. , 2013, , .		0
152	Results of a phase I trial of the proteasome inhibitor carfilzomib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL).. Journal of Clinical Oncology, 2013, 31, 7077-7077.	1.6	0
153	A Novel Therapeutic Approach In Acute Myeloid Leukemia (AML): In Vivo Preclinical Pharmacokinetic (PK), Pharmacodynamic (PD) and Antileukemia Activities Of Synthetic 2â€™-O-Methylphosphorothioate Mir-29b. Blood, 2013, 122, 3933-3933.	1.4	0
154	OSU-T315, An Integrin-Linked Kinase (ILK) Inhibitor, Induces Apoptosis By Targeting B Cell Receptor and CD49d Mediated AKT/ERK Activation In Chronic Lymphocytic Leukemia Cells. Blood, 2013, 122, 2523-2523.	1.4	0
155	A phase I trial of dabrafenib (BRAF inhibitor) and pazopanib in BRAF-mutated advanced malignancies.. Journal of Clinical Oncology, 2014, 32, TPS2628-TPS2628.	1.6	0
156	Abstract 4406: ROR1 targeted delivery of OSU-2S, a non-immunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle cell lymphomain-vitroandin-vivo. , 2015, , .		0
157	CD33 Targeted Immunoliposomal Delivery of OSU-2S, a Non-Immunosuppressive FTY720 Derivative, Mediates Selective Cytotoxicity in Acute Myeloid Leukemia. Blood, 2016, 128, 2748-2748.	1.4	0
158	ROR1 Targeted Immunoliposomal Delivery of OSU-2S Show Selective Cytotoxicity in t(1;19) Translocated B-ALL. Blood, 2019, 134, 3798-3798.	1.4	0
159	Comparison of Individualized Versus MAP-Bayesian Predicted AUC of Busulfan in FluBu4 Treated Patients Undergoing Allogeneic Transplant. Blood, 2020, 136, 19-20.	1.4	0